

## Supplemental Table 2

Prospective studies combining ipilimumab and radiation therapy for patients with unresectable and/or metastatic melanoma

Study Design	Title	Eligible patients (planned number for enrollment)	Lead Center	Treatment Details	Clinical Trial Identifier
Pilot Safety Study	Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy	Unresectable metastatic melanoma, failed one prior systemic therapy (20)	Stanford University	Induction ipilimumab at 3 mg/kg every 3 weeks, for 4 treatments Radiation therapy starting 2 days after first ipilimumab dose.	NCT01449279
Phase I	A Dose Escalation Phase I Study of Radiotherapy Administered in Combination with Anti-CTLA4 Monoclonal Antibody (Ipilimumab) in Patients with Unresectable Stage III or Stage IV Advanced Malignant Melanoma (Mel-Ipi-Rx)	Unresectable locally advanced or metastatic melanoma with at least one melanoma metastasis accessible to radiation therapy (30)	Institut Gustave Roussy	Induction ipilimumab at 10 mg/kg every 3 weeks, for 4 treatments, and then every 12 weeks. Radiation therapy dose escalated from 9 Gy to 24 Gy in 3 fractions (4 dose levels)	NCT01557114
Phase I	Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases	Metastatic melanoma with brain metastasis (24)	Thomas Jefferson University	Induction ipilimumab at different doses every 3 weeks, for 4 treatments. Radiation therapy is either whole brain (Arm A) and stereotactic radiosurgery (Arm B).	NCT01703507
Phase I/II	RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body RT Followed by Ipilimumab in Metastatic	Metastatic melanoma, previously treated or untreated (6-26)	University of Pennsylvania	Ipilimumab and stereotactic body radiation therapy	NCT01497808

	Melanoma				
Phase II	Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma	AJCC Stage III and IV melanoma with 5 or fewer sites of metastasis (unknown)	Comprehensive Cancer Centers of Nevada - Southwest	Ipilimumab and stereotactic ablative radiation therapy	NCT01565837
Phase II	Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma	Locally unresectable, metastatic melanoma with at least 2 distinct measureable metastatic sites (100)	New York University	Induction ipilimumab at 3 mg/kg every 3 weeks, for 4 treatments, with or without radiation therapy (30 Gy in 5 fractions over 1 week, starting 3 days before ipilimumab)	NCT01689974